H.R. 1082 · 119th Congress (2025–2027)
Shandra Eisenga Human Cell and Tissue Product Safety Act
This bill establishes civil penalties for violations of regulations governing the donation and handling of human cell and tissue products. It also requires the Food and Drug Administration (FDA) to report on the regulation of these products and to provide related information to stakeholders. (Human cell and tissue products are articles containing or consisting of human cells or tissues that are intended for use in a human recipient.)
Specifically, the bill establishes civil penalties for violations of the FDA’s regulations on donor eligibility and current good tissue practice for manufacturing and distributing human cell and tissue products.
Also, the bill requires the FDA to conduct workshops to educate stakeholders and facilitate discussion on the science and regulation of human cell and tissue products. The FDA must establish a public docket to receive written comments on this topic, and report to Congress with recommendations. The bill also requires the FDA to support the development of educational materials for health care professionals regarding organ, tissue, and eye donations and related topics.
Additionally, the bill requires the FDA to publish on its website educational materials about the Tissue Reference Group (a working group within the FDA) and best practices for obtaining a recommendation from them about human cell and tissue products. Also, annually for three years, the FDA must publish on its website information on inquiries submitted to the Tissue Reference Group and FDA registrations and inspections regarding human cell and tissue manufacturers.
Show official title
To require the Secretary of Health and Human Services to conduct a national, evidence-based education campaign to increase public and health care provider awareness regarding the potential risks and benefits of human cell and tissue products transplants, and for other purposes.
Passed House
Latest actionReferred to committee
This bill’s path
137 days after it was introduced
This is H.R. 1082’s recorded path, not a universal congressional workflow.
How bills become lawAll actionsIntroduced5 months
Passed House
Passed Senate
Sent to President
Signed into law
- Sponsor
- Rep. John R. Moolenaar (R-MI-2)
- Cosponsors
1 cosponsor
1 original · 0 later
- Rep. Debbie Dingell (D-MI-6)· Original · Feb 6, 2025
- Policy area
- Health
- Subjects
- Administrative law and regulatory procedures
- Civil actions and liability
- Congressional oversight
- Department of Health and Human Services
- Health programs administration and funding
- Health promotion and preventive care
- Organ and tissue donation and transplantation
On this page
Timeline
i
In chronological order. Major procedural acts are shown in full. Committee work and ordinary amendments fold in place where they happened, so they do not jump the sequence or stretch the timeline.
Introduced in House
Document: Introduced in House
Sources
- Congress.gov actionIntro-H
- Library of Congress
▸ 4 committee actions · Feb 6, 2025 – Jun 12, 2025
Referred to committee
Referred to the House Committee on Energy and Commerce.
Sources
- Congress.gov action
- House floor actions
Markup session held
Committee Consideration and Mark-up Session Held
Sources
- Congress.gov action
- House committee actions
Ordered reported
Ordered to be Reported by Voice Vote.
Sources
- Congress.gov action
- House committee actions
Reported by committee
Reported by the Committee on Energy and Commerce. H. Rept. 119-160.
Sources
- Congress.gov action
- House floor actions
Passed House
Congressional Record H2860–H2861
On motion to suspend the rules and pass the bill Agreed to by voice vote.
The House passed the bill.
Document: Engrossed in House
Sources
- Congress.gov action
- House floor actions
- Latest
Referred to committee
Received in the Senate and Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
Sources
- Congress.gov action
- Senate
Committees
- HouseEnergy and CommerceReferred Feb 6, 2025 · Markup Apr 29, 2025 · Reported Jun 12, 2025H. Rept. 119-160
Apr 29, 2025 · Markup
Apr 8, 2025 · Markup
Floor record
i
Explicit consideration evidence: the measure’s bill-status citation matched a GovInfo title, headline, or first paragraph. Incidental mentions are not listed.
Jun 23, 2025 · House · Considered under suspension of the rulesCongressional Record H2860–H2863
Shandra Eisenga Human Cell and Tissue Product Safety Act
Text & titles
i
Each distinct name Congress.gov recorded, once. Official, short, display, and popular titles stay distinct when the wording differs. The same wording is not repeated for every text version.
| Version | Date | Links |
|---|---|---|
| Introduced in House | ||
| Reported in House | ||
| Engrossed in House | ||
| Referred in Senate |
Titles (2)
To require the Secretary of Health and Human Services to conduct a national, evidence-based education campaign to increase public and health care provider awareness regarding the potential risks and benefits of human cell and tissue products transplants, and for other purposes.
Official title · Engrossed in House, Introduced in House
Shandra Eisenga Human Cell and Tissue Product Safety Act
Short title, Display title · Referred in Senate, Engrossed in House, Reported in House, Introduced in House